A phase II trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer.

BACKGROUND: Abiraterone acetate suppresses adrenal androgens and glucocorticoids by inhibition of CYP17; however, given the risk of mineralocorticoid excess, it is administered with glucocorticoids. We performed a phase 2, single-arm study, designed to assess the safety of abiraterone acetate withou...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer
Autors principals: McKay, R. R., Werner, L., Jacobus, S., Jones, A., Mostaghel, E. A., Marck, B. T., Choudhury, A., Pomerantz, M., Sweeney, C., Slovin, S. F., Morris, M. J., Kantoff, P. W., Taplin, M-E.
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6353689/
https://ncbi.nlm.nih.gov/pubmed/30427533
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.31836
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars